SEC Filing Summary: BioSig Technologies, Inc. (BSGM)
Business Context and Reporting Period
This Form 8-K Current Report was filed by BioSig Technologies, Inc. on March 5, 2025. The filing discloses the entry into a material definitive agreement for a private placement and provides an update on the company's At-The-Market (ATM) equity offering program.
Key Financial Metrics and Capital Raises
- Private Placement Proceeds: The company sold 758,514 shares of common stock and warrants to purchase an equal number of shares for aggregate consideration of $818,997.91.
- Private Placement Pricing: Shares were sold at $1.07974 per share. Warrants have an exercise price of $0.95474 per share, exercisable after six months and expiring in 3.5 years.
- ATM Offering Activity: Between January 17, 2025, and March 5, 2025, the company sold 4,413,807 shares under its ATM program.
- ATM Proceeds: Gross proceeds from the ATM sales totaled $4,028,498.73 at an average price of $0.912704 per share.
- Total Capital Raised (Reported Period): Approximately $4.85 million combined from the private placement and recent ATM sales.
Material Changes and Events
The primary material change is the execution of a Securities Purchase Agreement on March 5, 2025, raising nearly $819,000 from accredited investors. Additionally, the company reported significant activity under its existing ATM Sales Agreement with H.C. Wainwright & Co., LLC, having raised over $4 million in the first two months of 2025 against a total authorized capacity of $8.5 million.
Outlook, Risks, and Management Commentary
The filing does not contain forward-looking guidance, management commentary on operational performance, or specific risk factors beyond standard legal disclaimers regarding the securities offering. The transaction relies on exemptions under Section 4(a)(2) and Regulation D of the Securities Act. The filing explicitly states it does not constitute an offer to sell securities in jurisdictions where such an offer would be unlawful.
Investor Verification Checklist
- Verify the dilution impact of the 758,514 new shares and 758,514 warrant shares issued in the private placement.
- Confirm the remaining capacity under the $8.5 million ATM program (approximately $4.47 million remaining as of March 5, 2025).
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and redemption rights.
- Check the company's latest 10-K or 10-Q for current cash balances and burn rate to assess the runway provided by the ~$4.85 million in recent proceeds.
- Monitor the exercise timeline for the new warrants, which become exercisable six months post-issuance.